NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and internationally. It has a clinical trial collaboration agreement with MSD to evaluate tumor treating fields together with KEYTRUDA, an anti-PD-1 therapy; and a strategic alliance with the NYU Grossman School of Medicine's Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. NovoCure Limited was founded in 2000 and is based in Saint Helier, Jersey.
IPO Year: 2015
Exchange: NASDAQ
Website: novocure.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/16/2024 | $24.00 → $30.00 | Neutral → Buy | H.C. Wainwright |
| 11/20/2023 | $15.00 | Neutral | JP Morgan |
| 8/28/2023 | $85.00 → $25.00 | Buy → Neutral | H.C. Wainwright |
| 8/8/2023 | $45.00 | Neutral → Overweight | Piper Sandler |
| 8/4/2023 | $51.00 | Outperform | SVB Securities |
| 7/31/2023 | $33.00 | Underperform → In-line | Evercore ISI |
| 6/7/2023 | $53.00 → $46.00 | Underperform → Neutral | Wedbush |
| 5/16/2023 | $70.00 → $104.00 | Equal Weight → Overweight | Wells Fargo |
| 3/17/2023 | $99.00 → $50.00 | Neutral → Underweight | JP Morgan |
| 1/6/2023 | $89.00 → $107.00 | Overweight → Equal Weight | Wells Fargo |
4 - NovoCure Ltd (0001645113) (Issuer)
4 - NovoCure Ltd (0001645113) (Issuer)
4 - NovoCure Ltd (0001645113) (Issuer)
4 - NovoCure Ltd (0001645113) (Issuer)
3 - NovoCure Ltd (0001645113) (Issuer)
4 - NovoCure Ltd (0001645113) (Issuer)
4 - NovoCure Ltd (0001645113) (Issuer)
4 - NovoCure Ltd (0001645113) (Issuer)
4 - NovoCure Ltd (0001645113) (Issuer)
4 - NovoCure Ltd (0001645113) (Issuer)
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
SC 13G/A - NovoCure Ltd (0001645113) (Subject)
Novocure (NASDAQ:NVCR) announced today that it will present new data for its Tumor Treating Fields (TTFields) therapy for glioblastoma at the 29th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), November 21 – 24, Houston, Texas. Novocure will present the results of its work to design arrays that will allow efficient and stable delivery of TTFields in mouse studies as well as research identifying the optimal positioning of its newly approved Head Flexible Electrodes (HFE) transducer arrays for infratentorial brain tumors. Novocure will also present a new subgroup analysis of patients from the xCures real-world data platform that assesses the results of
New flexible arrays are lighter, thinner and designed to improve comfort for Optune Gio users Novocure (NASDAQ:NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved its new Head Flexible Electrode (HFE) transducer arrays for use with Optune Gio® for the treatment of adult patients with glioblastoma multiforme (GBM). Optune Gio is a wearable, portable device that produces alternating electric fields known as Tumor Treating Fields (TTFields), which are delivered through non-invasive, wearable arrays. TTFields exert physical forces on the electrically charged components of dividing cancer cells, which disrupt the rapid cell division exhibited by cancer cells. Th
Novocure (NASDAQ:NVCR) announced today that Christoph Brackmann has been appointed as the company's next Chief Financial Officer (CFO). Mr. Brackmann will join Novocure immediately as a Senior Financial Advisor and will transition to the role of CFO on January 1, 2025 when current CFO, Ashley Cordova, becomes CEO. Mr. Brackmann joins Novocure from Moderna, Inc. where he served as Senior Vice President of Finance since 2019. While at Moderna he established and built the finance team and oversaw the rapid expansion of the organization during the COVID-19 pandemic. "The addition of Christoph to our Novocure executive team comes at a pivotal time for the organization as we expand our product
Quarterly net revenues of $155 million, up 22% year-over-year, with record 4,113 active patients on therapy as of September 30, 2024 FDA approves Optune Lua® for the treatment of metastatic non-small cell lung cancer After 22 years as CEO, Asaf Danziger announces planned retirement at year end, will be succeeded by current CFO Ashley Cordova Christoph Brackmann appointed Chief Financial Officer, effective January 1, 2025 Novocure (NASDAQ:NVCR) today reported financial results for the third quarter ended September 30, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative thera
Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns
The first treatment of its kind for metastatic NSCLC, Optune Lua is approved for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic NSCLC who progressed on or after a platinum-based regimen Results of the pivotal Phase 3 LUNAR trial represent the first substantial improvement in median overall survival in more than 8 years for this patient population Optune Lua is a wearable treatment that delivers Tumor Treating Fields (TTFields), which exert physical forces on the electrically charged components of dividing cancer cells, resulting in cell death Novocure (NASDAQ:NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Op
Novocure (NASDAQ:NVCR) will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, October 30, to discuss the company's financial results for the three-month quarter and first nine months of the year that ended September 30, 2024. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link. The slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations p
Novocure (NASDAQ:NVCR) announced today it will present a real-world analysis of usage of its Tumor Treating Fields (TTFields) therapy and survival outcomes in newly diagnosed glioblastoma (ndGBM) patients at the European Society for Medical Oncology (ESMO) Congress 2024, September 13 – 17, Barcelona, Spain. The results of the real-world analysis suggest higher TTFields therapy device usage is significantly associated with improved survival outcomes in a broad population of ndGBM patients. Novocure's ESMO 2024 Data Presentation Details: Poster #459: Association of Tumor Treating Fields Device Usage with Survival in Newly Diagnosed GBM: A Real-World Analysis of Patients in the US Authors:
After 22 years as CEO, Asaf Danziger to retire at year end, will be succeeded by current CFO Ashley Cordova Wilco Groenhuysen to step down after 12 years as COO, Mukund Paravasthu current Senior Vice President, Product Development to transition to COO Novocure (NASDAQ:NVCR) announced today that Chief Executive Officer (CEO), Asaf Danziger, will retire at year-end 2024 and Novocure's Chief Financial Officer (CFO), Ashley Cordova, will succeed him as the company's next CEO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903420700/en/Asaf Danziger, Chief Executive Officer (Photo: Business Wire) Mr. Danziger, who has served a
Novocure (NASDAQ:NVCR) announced today that management will participate in the 2024 Wells Fargo Healthcare Conference on Wednesday, September 4, 2024. William Doyle, Novocure's Executive Chairman, will take part in a fireside chat at 4:30 p.m. EST, as well as one-on-one meetings with investors throughout the event. A live audio webcast of this presentation can be accessed from the Investor Relations page of Novocure's website, www.novocure.com/investor-relations, and will be available for replay for at least 14 days following the event. Novocure's corporate presentation is updated periodically, and the current presentation can be accessed from the Investor Relations page of Novocure's w
H.C. Wainwright upgraded NovoCure from Neutral to Buy and set a new price target of $30.00 from $24.00 previously
JP Morgan resumed coverage of NovoCure with a rating of Neutral and set a new price target of $15.00
H.C. Wainwright downgraded NovoCure from Buy to Neutral and set a new price target of $25.00 from $85.00 previously
Piper Sandler upgraded NovoCure from Neutral to Overweight and set a new price target of $45.00
SVB Securities initiated coverage of NovoCure with a rating of Outperform and set a new price target of $51.00
Evercore ISI upgraded NovoCure from Underperform to In-line and set a new price target of $33.00
Wedbush upgraded NovoCure from Underperform to Neutral and set a new price target of $46.00 from $53.00 previously
Wells Fargo upgraded NovoCure from Equal Weight to Overweight and set a new price target of $104.00 from $70.00 previously
JP Morgan downgraded NovoCure from Neutral to Underweight and set a new price target of $50.00 from $99.00 previously
Wells Fargo downgraded NovoCure from Overweight to Equal Weight and set a new price target of $107.00 from $89.00 previously
For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c
8-K - NovoCure Ltd (0001645113) (Filer)
10-Q - NovoCure Ltd (0001645113) (Filer)
8-K - NovoCure Ltd (0001645113) (Filer)
8-K - NovoCure Ltd (0001645113) (Filer)
S-8 POS - NovoCure Ltd (0001645113) (Filer)
S-8 POS - NovoCure Ltd (0001645113) (Filer)
S-8 POS - NovoCure Ltd (0001645113) (Filer)
S-8 POS - NovoCure Ltd (0001645113) (Filer)
S-8 POS - NovoCure Ltd (0001645113) (Filer)
S-8 POS - NovoCure Ltd (0001645113) (Filer)
Quarterly net revenues of $155 million, up 22% year-over-year, with record 4,113 active patients on therapy as of September 30, 2024 FDA approves Optune Lua® for the treatment of metastatic non-small cell lung cancer After 22 years as CEO, Asaf Danziger announces planned retirement at year end, will be succeeded by current CFO Ashley Cordova Christoph Brackmann appointed Chief Financial Officer, effective January 1, 2025 Novocure (NASDAQ:NVCR) today reported financial results for the third quarter ended September 30, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative thera
Novocure (NASDAQ:NVCR) will report financial results for the third quarter 2024 on Wednesday, October 30, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast at 8:00 a.m. EDT, October 30, to discuss the company's financial results for the three-month quarter and first nine months of the year that ended September 30, 2024. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link. The slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations p
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Novocure (NASDAQ:NVCR) today reported financial results for the quarter ended June 30, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). "The second quarter was a period of consistent execution at Novocure," said Asaf Danziger, Novocure's Chief Executive Officer. "We began the year with three k
Novocure (NASDAQ:NVCR) announced today that it will report financial results for the second quarter 2024 on Thursday, July 25, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company's financial results for the three and six months ended June 30, 2024, at 8:00 a.m. EDT on Thursday, July 25, 2024. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link. The slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of
Quarterly net revenues of $139 million, up 13% year-over-year, with 3,845 active patients on therapy as of March 31, 2024 Phase 3 METIS trial in brain metastases from non-small cell lung cancer met primary endpoint and will be presented as late-breaking abstract at ASCO 2024 LUNAR PMA application for TTFields in NSCLC Day 100 FDA meeting complete Novocure (NASDAQ:NVCR) today reported financial results for the quarter ended March 31, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). "The first quarter was a period of strong ex
Novocure (NASDAQ:NVCR) announced today that it will report financial results for the first quarter 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company's financial results for the three months ended March 31, 2024, at 8:00 a.m. EDT on Thursday, May 2, 2024. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link. The slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure's w
The METIS trial demonstrated 21.9 months median time to intracranial progression for patients treated with Tumor Treating Fields and supportive care compared to 11.3 months for patients treated with supportive care alone Novocure to host investor conference call at 8 a.m. EDT Novocure (NASDAQ:NVCR) today announced the phase 3 METIS clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for adult patients treated with Tumor Treating Fields (TTFields) therapy and supportive care compared to supportive care alone in the treatment of patients with 1-10 brain metastases from non-small cell lung cancer (NSCLC) followi
Preliminary full year 2023 net revenues of $509 million and fourth quarter net revenues of $134 million PMA application for TTFields in NSCLC submitted for review to U.S. Food and Drug Administration Nicholas Leupin M.D., Ph.D. appointed as Novocure Chief Medical Officer, effective January 1, 2024 Novocure to present at the 42nd Annual J.P. Morgan Healthcare Conference at 7:30 a.m. PST on Wednesday, January 10, 2024 Novocure (NASDAQ:NVCR) today reported preliminary unaudited financial results and operational updates for the quarter and full year ended December 31, 2023. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by
Quarterly net revenues of $127 million with 3,639 active patients on therapy as of September 30, 2023 Novocure (NASDAQ:NVCR) today reported financial results for the quarter ended September 30, 2023. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). "We are focused on extending survival in some of the most aggressive forms of cancer," said Asaf Danziger, Novocure's Chief Executive Officer. "This quarter we continued our very successful launch in France and took significant strides in the rollout of our new arrays, which are thinner, li
Novocure (NASDAQ:NVCR) announced today that it will report financial results for the third quarter 2023 on Thursday, October 26, 2023, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company's financial results for the three and nine months ended September 30, 2023, at 8 a.m. EDT on Thursday, October 26, 2023. To access the conference call by phone, use the following conference call registration link and dial-in details will be provided. To access the webcast, use the following webcast registration link. The slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations
Novocure (NASDAQ:NVCR) announced today that Christoph Brackmann has been appointed as the company's next Chief Financial Officer (CFO). Mr. Brackmann will join Novocure immediately as a Senior Financial Advisor and will transition to the role of CFO on January 1, 2025 when current CFO, Ashley Cordova, becomes CEO. Mr. Brackmann joins Novocure from Moderna, Inc. where he served as Senior Vice President of Finance since 2019. While at Moderna he established and built the finance team and oversaw the rapid expansion of the organization during the COVID-19 pandemic. "The addition of Christoph to our Novocure executive team comes at a pivotal time for the organization as we expand our product
Mr. Scannell and Ms. Lane will Add Valuable Medical Technology, Finance and Corporate Governance Experience to Expanded Eight-Member Board Masimo Corporation (NASDAQ:MASI), a leading global medical innovator, today announced the appointments of Timothy J. Scannell and Wendy E. Lane to the Company's Board of Directors (the "Board"), effective immediately. Following these appointments, the Board will consist of eight directors. Quentin Koffey, Lead Independent Director of Masimo, stated, "We are pleased to welcome Tim and Wendy as our newest independent directors. Both are high-caliber professionals who will bring critical perspectives to the Board and possess expertise that closely aligns
After 22 years as CEO, Asaf Danziger to retire at year end, will be succeeded by current CFO Ashley Cordova Wilco Groenhuysen to step down after 12 years as COO, Mukund Paravasthu current Senior Vice President, Product Development to transition to COO Novocure (NASDAQ:NVCR) announced today that Chief Executive Officer (CEO), Asaf Danziger, will retire at year-end 2024 and Novocure's Chief Financial Officer (CFO), Ashley Cordova, will succeed him as the company's next CEO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903420700/en/Asaf Danziger, Chief Executive Officer (Photo: Business Wire) Mr. Danziger, who has served a
Medical Device Leaders Shlomi Nachman and Timothy Scannell to join Board of DirectorsBOSTON, July 16, 2024 /PRNewswire/ -- CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, today announced the following appointments to the Company's Board of Directors, effective July 11, 2024: Shlomi Nachman, former Company Group Chairman of Cardiovascular and Specialty Solutions and Vision Groups within Johnson & Johnson's Medical Devices sectorTimothy Scannell, former President and Chief Operating Officer of Stryker"We are excited
Novocure (NASDAQ:NVCR) today announced the appointment of Nicolas Leupin, M.D., Ph.D., MBA to the role of Chief Medical Officer. Dr. Leupin brings a proven track record of leadership and accomplishment in the biotechnology and pharmaceutical industries, as well as extensive experience as a medical oncologist and educator. At Novocure, Dr. Leupin will oversee medical affairs, medical safety, and clinical development operations as the company advances its clinical pipeline and prepares to treat an expanded patient population. "It is a pleasure to welcome Dr. Leupin to Novocure as our new Chief Medical Officer," said Asaf Danziger, Novocure's Chief Executive Officer. "Nicolas brings a wealth
International industry executive Piet Hinoul joins Virtual Incision as chief medical officer, Dmitry Oleynikov transitions to chief surgeon Virtual Incision Corporation, a medical device company developing the world's first miniaturized robotic-assisted surgery (RAS) system, today announced the appointment of global healthcare executive Piet Hinoul, MD, PhD, as chief medical officer (CMO). The company's current CMO Dmitry Oleynikov, MD, FACS will take on the newly established role of chief surgeon, focusing on the research and development of new RAS technology. The expansion of the team strengthens Virtual Incision at a transformative point in its trajectory as it develops new market growt
PALM BEACH GARDENS, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AeroClean Technologies ("AeroClean" or the "Company") (NASDAQ:AERC), a pathogen elimination technology company harnessing patented UV-C LED technology with Pūrgo™ to significantly reduce and remove harmful pathogens to keep work, play and life going, today announced the appointment of Timothy J. Scannell, former President and Chief Operating Officer at Stryker, to its Board of Directors (the "Board"). On May 11, 2022, the Board appointed Mr. Scannell as a new director on the Board, chair of the Nominating and Corporate Governance Committee and a member of the Compensation Committee. Mr. Scannell brings over 30 years of experienc
Novocure (NASDAQ:NVCR) today announced that William (Bill) Burke has been promoted to Chief Human Resources Officer, effective September 1, 2021. This appointment reflects the importance of Novocure's team members to our anticipated growth. Mr. Burke joined Novocure in 2014 and most recently served as the Senior Vice President of Global Human Resources. He has had extensive experience as a human resources leader for companies such as Arrow Electronics, ThermoFisher Scientific, Novartis Consumer Health, Cadbury Schweppes and PepsiCo. Mr. Burke holds a bachelor's degree in Business and Industrial Relations from the University of Bridgeport, and he has attended management development programs
4 analysts have expressed a variety of opinions on NovoCure (NASDAQ:NVCR) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 3 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 1 0 0 2M Ago 0 0 0 0 0 3M Ago 0 1 1 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $23.0, a high estimate of $2
Evercore ISI Group analyst Vijay Kumar maintains NovoCure (NASDAQ:NVCR) with a In-Line and raises the price target from $14.5 to $20.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume NVO PUT SWEEP BULLISH 07/19/24 $135.00 $44.5K 2.0K 947 LLY CALL TRADE BEARISH 06/14/24 $905.00 $45.0K
7 analysts have shared their evaluations of NovoCure (NASDAQ:NVCR) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 2 5 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 1 1 0 0 3M Ago 0 1 3 0 0 Analysts have recently evaluated NovoCure and provided 12-month price targets. The average target is $25.29, accompanied by a high estimate of $42.00 and a low estimate of $17.00. This current average has decreased by 3
HC Wainwright & Co. analyst Emily Bodnar reiterates NovoCure (NASDAQ:NVCR) with a Neutral and maintains $22 price target.
Patients treated with TTFields therapy and BSC exhibited a median time to intracranial progression of 21.9 months compared to 11.3 months in patients treated with BSC alone (hazard ratio=0.67; P=0.016). Median TTFields therapy duration was 16 weeks and median usage was 67%. Baseline patient demographics and characteristics were well balanced between arms.
U.S. stocks were higher, with the Nasdaq Composite gaining around 100 points on Monday. Shares of Overseas Shipholding Group, Inc. (NYSE:OSG) rose sharply during Monday's session after the company announced it entered into a definitive merger agreement to be acquired by Saltchuk Resources. The transaction is valued at an aggregate equity value of around $653 million and a total transaction value of $950 million. Overseas Shipholding Group shares climbed 22.8% to $8.43 on Monday. Here are some other big stocks recording gains in today's session. Hims & Hers Health, Inc. (NYSE:HIMS) shares jumped 30.5% to $19.01 after the company announced the addition of GLP-1 injections to it
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. Below are some instances of options activity happening in the Health Care sector: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume CVS CALL TRADE BEARISH 06/07/24 $56.00 $38.2K 765 2.1K BMRN CALL SWEEP BEARISH 09/20/